The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomized clinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemic agents (LEAD 1-6 program). Liraglutide is shown to have advantages when used by patients with an excess body mass and obesity, those at risk of cardiovascular diseases and prone to develop hypoglycemia. Patients treated with liraglutide (1.8 mg) more frequently achieved the desired efficacy endpoints (HbA(1c). < 7%, reduced body mass and AP control) of than those using traditional therapy (24 vs 3-14%).